In previous studies, the effectiveness of low-dose IL-2 on Treg cell proliferation and disease remission in psoriatic arthritis (PsA) (46), systemic lupus erythematosus (SLE) (47), and Sjögren’s syndrome (SS) (48) has been demonstrated, but side effects have not been evaluated. This evidence concerns the gene IL2 and psoriatic arthritis.